Conventional subcutaneous insulin therapy faces limitations in patient adherence and carries a persistent risk of hypoglycemia, primarily due to the challenges of achieving precise dosing. To address ...

Good morning, and welcome to the Insulet Corporation First Quarter Earnings Call. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, ...

Earnings call Insulet delivered Q1 2026 revenue of $762M, up 34% reported and 30% constant currency YoY, with Omnipod revenue up 33% constant currency and adjusted ...

Children and young people with type 1 diabetes (T1D) often require support when faced with the common illnesses and infections of childhood. Illnesses particularly associated with fever can cause ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has shared new ...

Insulin pumps are the most advanced insulin delivery technology available today for people with type 1 and type 2 diabetes. An insulin pump replaces injections with a syringe or insulin pen, using an ...

Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call Transcript August 7, 2025 Insulet Corporation beats earnings expectations. Reported EPS is $1.17, expectations were $0.93. Operator: Good ...

A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...

A person wears the G7 (on the left arm) and t:slim X2 (on the waist). [Image courtesy of Tandem Diabetes Care] It’s been a busy couple of years for Tandem Diabetes Care (Nasdaq:TNDM) and it doesn’t ...

Department of Bioscience and Biomedical Engineering, Indian Institute of Technology-Bhilai, Durg, 491002, CG India Department of Chemistry, Indian Institute of Technology-Bhilai, Durg, 491002, CG ...